Dabrafenib - CAS# 1195765-45-7 size:2mg solid LIM domain kinases as potential

LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2

tight-binding kinetics) of LpxC from Rhizobium leguminosarum (Ki=340 nM)

b-AP15 induces apoptosis by cathepsin D-dependent caspase-cleavage (IC50 ~0

5E)-1-((S)-2-amino-3-phenylpropanoyl)-3

Dabrafenib - CAS# 1195765-45-7 size:2mg solid LIM domain kinases as potentialDabrafenib, CAS No. 1195765 45 7, also known as GSK2118436 , is an orally bioavailable inhibitor of B raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B raf belongs to the the raf mil family of serine threonine protein kinases and plays a role in regulating the MAP kinase ERKs signaling